<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39384979</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>Vaccination against rapidly evolving pathogens and the entanglements of memory.</ArticleTitle><Pagination><StartPage>2015</StartPage><EndPage>2023</EndPage><MedlinePgn>2015-2023</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-024-01970-2</ELocationID><Abstract><AbstractText>Immune memory determines infection risk and responses to future infections and vaccinations over potentially decades of life. Despite its centrality, the dynamics of memory to antigenically variable pathogens remains poorly understood. This Review examines how past exposures shape B cell responses to vaccinations with influenza and SARS-CoV-2. An overriding feature of vaccinations with these pathogens is the recall of primary responses, often termed 'imprinting' or 'original antigenic sin'. These recalled responses can inhibit the generation of new responses unless some incompletely defined conditions are met. Depending on the context, immune memory can increase or decrease the total neutralizing antibody response to variant antigens, with apparent consequences for protection. These effects are easier to measure experimentally than epidemiologically, but there is evidence that both early and recent exposures influence vaccine effectiveness. A few immunological interactions between adaptive immune responses and antigens might explain the seemingly discrepant effects of memory. Overall, the complex observations point to a need for more quantitative approaches to integrate high-dimensional immune data from populations with diverse exposure histories. Such approaches could help identify optimal vaccination strategies against antigenically diverse pathogens.</AbstractText><CopyrightInformation>© 2024. Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cobey</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5298-8979</Identifier><AffiliationInfo><Affiliation>Department of Ecology and Evolution, University of Chicago, Chicago, IL, USA. cobey@uchicago.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>75N93019C00051</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75N93019C00051</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384979</ArticleId><ArticleId IdType="doi">10.1038/s41590-024-01970-2</ArticleId><ArticleId IdType="pii">10.1038/s41590-024-01970-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davenport, F. M. &amp; Hennessy, A. V. Predetermination by infection and by vaccination of antibody response to influenza virus vaccines. J. Exp. Med. 106, 835–850 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13481247</ArticleId><ArticleId IdType="pmc">2136834</ArticleId><ArticleId IdType="doi">10.1084/jem.106.6.835</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport, F. M., Hennessy, A. V., Stuart-Harris, C. H. &amp; Francis, T. Jr. Epidemiology of influenza; comparative serological observations in England and the United States. Lancet 269, 469–474 (1955).</Citation><ArticleIdList><ArticleId IdType="pubmed">13252891</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(55)93328-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen, K. E., Davenport, F. M., Hennessy, A. V. &amp; Francis, T. Jr. Characterization of influenza antibodies by serum absorption. J. Exp. Med. 104, 199–209 (1956).</Citation><ArticleIdList><ArticleId IdType="pubmed">13345965</ArticleId><ArticleId IdType="pmc">2136660</ArticleId><ArticleId IdType="doi">10.1084/jem.104.2.199</ArticleId></ArticleIdList></Reference><Reference><Citation>de St Groth, F. &amp; Webster, R. G. Disquisitions of original antigenic sin. I. Evidence in man. J. Exp. Med. 124, 331–345 (1966).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.124.3.331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskins, T. W., Davies, J., Smith, A. J., Miller, C. &amp; Allchin, A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet 313, 33–35 (1979).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(79)90468-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Keitel, W. A., Cate, T. R. &amp; Couch, R. B. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am. J. Epidemiol. 127, 353–364 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3337087</ArticleId><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a114809</ArticleId></ArticleIdList></Reference><Reference><Citation>Keitel, W. A., Cate, T. R., Couch, R. B., Huggins, L. L. &amp; Hess, K. R. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 15, 1114–1122 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9269055</ArticleId><ArticleId IdType="doi">10.1016/S0264-410X(97)00003-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, W. E., de Bruijn, I. A., Palache, A. M., Westendorp, R. G. &amp; Osterhaus, A. D. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch. Intern. Med. 159, 182–188 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9927102</ArticleId><ArticleId IdType="doi">10.1001/archinte.159.2.182</ArticleId></ArticleIdList></Reference><Reference><Citation>Gostic, K. M., Ambrose, M., Worobey, M. &amp; Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354, 722–726 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27846599</ArticleId><ArticleId IdType="pmc">5134739</ArticleId><ArticleId IdType="doi">10.1126/science.aag1322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gostic, K. M. et al. Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics. PLoS Pathog. 15, e1008109 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31856206</ArticleId><ArticleId IdType="pmc">6922319</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1008109</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo, P., McLean, H. Q., Belongia, E. A. &amp; Cobey, S. Earliest infections predict the age distribution of seasonal influenza A cases. eLife 9, 19001875 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.50060</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang, T. K. et al. Investigation of the impact of childhood immune imprinting on birth year-specific risk of clinical infection during influenza A virus epidemics in Hong Kong. J. Infect. Dis. 228, 169–172 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36637115</ArticleId><ArticleId IdType="pmc">10345470</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad009</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos, M. &amp; Ellebedy, A. H. Immunological imprinting: understanding COVID-19. Immunity 56, 909–913 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37105169</ArticleId><ArticleId IdType="pmc">10113596</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2023.04.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, C.-Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950–960 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38749479</ArticleId><ArticleId IdType="doi">10.1038/s41586-024-07539-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148–156 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37993710</ArticleId><ArticleId IdType="pmc">10764275</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06753-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. H., Skountzou, I., Compans, R. &amp; Jacob, J. Original antigenic sin responses to influenza viruses. J. Immunol. 183, 3294–3301 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19648276</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0900398</ArticleId></ArticleIdList></Reference><Reference><Citation>Monto, A. S., Malosh, R. E., Petrie, J. G. &amp; Martin, E. T. The doctrine of original antigenic sin: separating good from evil. J. Infect. Dis. 215, 1782–1788 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28398521</ArticleId><ArticleId IdType="pmc">5853211</ArticleId><ArticleId IdType="doi">10.1093/infdis/jix173</ArticleId></ArticleIdList></Reference><Reference><Citation>Linderman, S. L. &amp; Hensley, S. E. Antibodies with ‘original antigenic sin’ properties are valuable components of secondary immune responses to influenza viruses. PLoS Pathog. 12, e1005806 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27537358</ArticleId><ArticleId IdType="pmc">4990287</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1005806</ArticleId></ArticleIdList></Reference><Reference><Citation>Yewdell, J. W. &amp; Santos, J. J. S. Original antigenic sin: how original? How sinful? Cold Spring Harb. Perspect. Med. 11, a038786 (2021).</Citation></Reference><Reference><Citation>Erbelding, E. J. et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347–354 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29506129</ArticleId><ArticleId IdType="pmc">6279170</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiy103</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996–1000 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25414313</ArticleId><ArticleId IdType="pmc">4246172</ArticleId><ArticleId IdType="doi">10.1126/science.1256427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181–193 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21220454</ArticleId><ArticleId IdType="pmc">3023136</ArticleId><ArticleId IdType="doi">10.1084/jem.20101352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellebedy, A. H. et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl Acad. Sci. USA 111, 13133–13138 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25157133</ArticleId><ArticleId IdType="pmc">4246941</ArticleId><ArticleId IdType="doi">10.1073/pnas.1414070111</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews, S. F. et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl. Med. 7, 316ra192 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26631631</ArticleId><ArticleId IdType="pmc">4770855</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aad0522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn, K. B. et al. Human B cell lineages associated with germinal centers following influenza vaccination are measurably evolving. eLife 10, e70873 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34787567</ArticleId><ArticleId IdType="pmc">8741214</ArticleId><ArticleId IdType="doi">10.7554/eLife.70873</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry, C. et al. Influenza virus vaccination elicits poorly adapted B cell responses in elderly individuals. Cell Host Microbe 25, 357–366 (2019).</Citation></Reference><Reference><Citation>Lee, J. et al. Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations. Cell Host Microbe 25, 367–376 (2019).</Citation></Reference><Reference><Citation>Lee, J. et al. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat. Med. 22, 1456–1464 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27820605</ArticleId><ArticleId IdType="pmc">5301914</ArticleId><ArticleId IdType="doi">10.1038/nm.4224</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugan, H. L. et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci. Transl. Med. 12, eabd3601 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33298562</ArticleId><ArticleId IdType="pmc">8115023</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abd3601</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh, Z. et al. Factors associated with prolonged respiratory virus detection from polymerase chain reaction of nasal specimens collected longitudinally in healthy children in a US birth cohort. J. Pediatr. Infect. Dis. Soc. 13, 189–195 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piae009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy, G. et al. Increased influenza severity in children in the wake of SARS-CoV-2. Influenza Other Respir. Viruses 17, e13178 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13178</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, H. E. et al. The Nicaraguan Pediatric Influenza Cohort Study, 2011–2019: influenza incidence, seasonality, and transmission. Clin. Infect. Dis. 76, e1094–e1103 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35639580</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac420</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912–925 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38490198</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904–911 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38490197</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.02.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsoussi, W. B. et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature 617, 592–598 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37011668</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06025-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia, A. et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature 621, 592–601 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37648855</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06487-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño, J. M., Singh, G., Simon, V., Krammer, F. &amp; PVI study group. Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies. Lancet Microbe 4, e569 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37141905</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(23)00118-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, J. S. et al. Human germinal centres engage memory and naive B cells after influenza vaccination. Nature 586, 127–132 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32866963</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2711-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobey, S. et al. Poor immunogenicity, not vaccine strain egg adaptation, may explain the low H3N2 influenza vaccine effectiveness in 2012–2013. Clin. Infect. Dis. 67, 327–333 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29471464</ArticleId><ArticleId IdType="doi">10.1093/cid/ciy097</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiepers, A. et al. Molecular fate-mapping of serum antibody responses to repeat immunization. Nature 615, 482–489 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36646114</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-05715-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372–1374 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33691060</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2101667</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587–599 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38395697</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.01.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda, L. B. et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell 185, 1588–1601 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35413241</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.03.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape, K. A. et al. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. Cell Rep. 37, 109823 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34610291</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109823</ArticleId></ArticleIdList></Reference><Reference><Citation>Auladell, M. et al. Influenza virus infection history shapes antibody responses to influenza vaccination. Nat. Med. 8, 363–372 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01690-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, K. et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature 607, 356–359 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35523247</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04830-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pušnik, J. et al. Vaccination impairs de novo immune response to Omicron breakthrough infection, a precondition for the original antigenic sin. Nat. Commun. 15, 3102 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38600072</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-47451-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, M. G. et al. Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010–11. Vaccine 34, 981–988 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26813801</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.119</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox, A. et al. Opposing effects of prior infection versus prior vaccination on vaccine immunogenicity against influenza A(H3N2) viruses. Viruses 14, 470 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35336877</ArticleId><ArticleId IdType="doi">10.3390/v14030470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA 114, 12578–12583 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29109276</ArticleId><ArticleId IdType="doi">10.1073/pnas.1712377114</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouma, S. et al. Comparison of human H3N2 antibody responses elicited by egg-based, cell-based, and recombinant protein-based influenza vaccines during the 2017–2018 season. Clin. Infect. Dis. 71, 1447–1453 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31598646</ArticleId><ArticleId IdType="doi">10.1093/cid/ciz996</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery, B., Lipsitch, M. &amp; Cobey, S. Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jiae220 (2024).</Citation></Reference><Reference><Citation>Gouma, S. et al. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat. Commun. 11, 4566 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32917903</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-18465-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. H., Davis, W. G., Sambhara, S. &amp; Jacob, J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl Acad. Sci. USA 109, 13751–13756 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22869731</ArticleId><ArticleId IdType="doi">10.1073/pnas.0912458109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera. Preprint at bioRxiv https://doi.org/10.1101/2024.04.05.588359 (2024).</Citation></Reference><Reference><Citation>Hobson, D., Curry, R. L., Beare, A. S. &amp; Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 70, 767–777 (1972).</Citation><ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34588689</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands, J. M. et al. Waning of vaccine effectiveness against moderate and severe COVID-19 among adults in the US from the VISION network: test negative, case–control study. BMJ 379, e072141 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36191948</ArticleId><ArticleId IdType="doi">10.1136/bmj-2022-072141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34614327</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2114114</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi, E. K. et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA 327, 639–651 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35060999</ArticleId><ArticleId IdType="pmc">8848203</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.0470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063–1071 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35189624</ArticleId><ArticleId IdType="pmc">9117141</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01753-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34995482</ArticleId><ArticleId IdType="pmc">8733787</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge, S. et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 Omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect. Dis. 22, 1313–1320 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35658998</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00292-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, B. et al. Effectiveness of CoronaVac and BNT162b2 vaccines against severe acute respiratory syndrome coronavirus 2 Omicron BA.2 infections in Hong Kong. J. Infect. Dis. 226, 1382–1384 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36054016</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiac360</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, R. et al. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. Lancet Reg. Health West. Pac. 32, 100660 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36591327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch, M., Goldstein, E., Ray, G. T. &amp; Fireman, B. Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. Epidemiol. Infect. 147, e306 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31774051</ArticleId><ArticleId IdType="doi">10.1017/S0950268819001961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn, R., Schrag, S. J., Verani, J. R. &amp; Lipsitch, M. Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines. Am. J. Epidemiol. 191, 800–811 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35081612</ArticleId><ArticleId IdType="doi">10.1093/aje/kwac015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray, G. T. et al. Depletion-of-susceptibles bias in analyses of intra-season waning of influenza vaccine effectiveness. Clin. Infect. Dis. 70, 1484–1486 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31351439</ArticleId><ArticleId IdType="doi">10.1093/cid/ciz706</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski, D. M. et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 season. Clin. Infect. Dis. 63, 21–32 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27025838</ArticleId><ArticleId IdType="doi">10.1093/cid/ciw176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmit, S. E. et al. Influenza vaccine effectiveness in the community and the household. Clin. Infect. Dis. 56, 1363–1369 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23413420</ArticleId><ArticleId IdType="pmc">3693492</ArticleId><ArticleId IdType="doi">10.1093/cid/cit060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones-Gray, E., Robinson, E. J., Kucharski, A. J., Fox, A. &amp; Sullivan, S. G. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir. Med. 11, 27–44 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36152673</ArticleId><ArticleId IdType="pmc">9780123</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(22)00266-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmit, S. E. et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin. Infect. Dis. 58, 319–327 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24235265</ArticleId><ArticleId IdType="pmc">4007111</ArticleId><ArticleId IdType="doi">10.1093/cid/cit736</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean, H. Q. et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin. Infect. Dis. 59, 1375–1385 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25270645</ArticleId><ArticleId IdType="pmc">4207422</ArticleId><ArticleId IdType="doi">10.1093/cid/ciu680</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenciano, M. et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case–Control Study, Europe 2014/15. Euro Surveill. 21, 30139 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.7.30139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly, H. et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect. Dis. 23, 816–827 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36913963</ArticleId><ArticleId IdType="pmc">10079373</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00058-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha, N. K. et al. Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infect. Dis. 10, ofad209 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37274183</ArticleId><ArticleId IdType="pmc">10234376</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad209</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge, S., Pastor-Barriuso, R. &amp; Hernán, M. A. The imprinting effect of COVID-19 vaccines: an expected selection bias in observational studies. BMJ 381, e074404 (2023).</Citation></Reference><Reference><Citation>Hernán, M. A. &amp; Monge, S. Selection bias due to conditioning on a collider. BMJ 381, 1135 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37286200</ArticleId><ArticleId IdType="doi">10.1136/bmj.p1135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood, N. et al. Influenza vaccine effectiveness among children: 2011–2020. Pediatrics 151, e2022059922 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36960655</ArticleId><ArticleId IdType="doi">10.1542/peds.2022-059922</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanks, G. D., Hussell, T. &amp; Brundage, J. F. Epidemiological isolation causing variable mortality in island populations during the 1918–1920 influenza pandemic. Influenza Other Respir. Viruses 6, 417–423 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-2659.2011.00332.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery, B. et al. Influence of birth cohort on effectiveness of 2015–2016 influenza vaccine against medically attended illness due to 2009 pandemic influenza A(H1N1) virus in the United States. J. Infect. Dis. 218, 189–196 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29361005</ArticleId><ArticleId IdType="pmc">6009604</ArticleId><ArticleId IdType="doi">10.1093/infdis/jix634</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski, D. M. et al. Beyond antigenic match: possible agent–host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015–2016 season in Canada. J. Infect. Dis. 216, 1487–1500 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29029166</ArticleId><ArticleId IdType="pmc">5853508</ArticleId><ArticleId IdType="doi">10.1093/infdis/jix526</ArticleId></ArticleIdList></Reference><Reference><Citation>Linderman, S. L. et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season. Proc. Natl Acad. Sci. USA 111, 15798–15803 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25331901</ArticleId><ArticleId IdType="pmc">4226110</ArticleId><ArticleId IdType="doi">10.1073/pnas.1409171111</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, K.-Y. A. et al. Focused antibody response to influenza linked to antigenic drift. J. Clin. Invest. 125, 2631–2645 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26011643</ArticleId><ArticleId IdType="pmc">4613558</ArticleId><ArticleId IdType="doi">10.1172/JCI81104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissling, E. et al. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort. Euro Surveill. 24, 1900604 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31796152</ArticleId><ArticleId IdType="pmc">6891946</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.48.1900604</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski, D. M. et al. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Euro Surveill. 24, 1900585 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31771709</ArticleId><ArticleId IdType="pmc">6864978</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.46.1900585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye, S. G., Avery, D. T., Deenick, E. K. &amp; Hodgkin, P. D. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J. Immunol. 170, 686–694 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12517929</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.170.2.686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebeis, B. J. et al. Activation of virus-specific memory B cells in the absence of T cell help. J. Exp. Med. 199, 593–602 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14769849</ArticleId><ArticleId IdType="pmc">2211828</ArticleId><ArticleId IdType="doi">10.1084/jem.20030091</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott, R. K. et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity 48, 133–146 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29287996</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.11.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas, J. M. J. et al. Antibodies from primary humoral responses modulate recruitment of naive B cells during secondary responses. Immunity 55, 1856–1871 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35987201</ArticleId><ArticleId IdType="pmc">9350677</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.07.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, M. et al. Targeted elimination of immunodominant B cells drives the germinal center reaction toward subdominant epitopes. Cell Rep. 21, 3672–3680 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29281817</ArticleId><ArticleId IdType="pmc">5771444</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.12.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. Germinal center B cells govern their own fate via antibody feedback. J. Exp. Med. 210, 457–464 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23420879</ArticleId><ArticleId IdType="pmc">3600904</ArticleId><ArticleId IdType="doi">10.1084/jem.20120150</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyster, J. G. &amp; Wilson, P. C. Antibody modulation of B cell responses—incorporating positive and negative feedback. Immunity 57, 1466–1481 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38986442</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Viant, C. et al. Antibody affinity shapes the choice between memory and germinal center B cell fates. Cell 183, 1298–1311 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33125897</ArticleId><ArticleId IdType="pmc">7722471</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.09.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin, A. D., Shulman, Z. &amp; Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509, 637–640 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24805232</ArticleId><ArticleId IdType="pmc">4271732</ArticleId><ArticleId IdType="doi">10.1038/nature13300</ArticleId></ArticleIdList></Reference><Reference><Citation>Victora, G. D. et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143, 592–605 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21074050</ArticleId><ArticleId IdType="pmc">3035939</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2010.10.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwickert, T. A. et al. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J. Exp. Med. 208, 1243–1252 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21576382</ArticleId><ArticleId IdType="pmc">3173244</ArticleId><ArticleId IdType="doi">10.1084/jem.20102477</ArticleId></ArticleIdList></Reference><Reference><Citation>Toellner, K.-M., Sze, D. M.-Y. &amp; Zhang, Y. What are the primary limitations in B-cell affinity maturation, and how much affinity maturation can we drive with vaccination? A role for antibody feedback. Cold Spring Harb. Perspect. Biol. 10, a028795 (2018).</Citation></Reference><Reference><Citation>Angeletti, D. et al. Outflanking immunodominance to target subdominant broadly neutralizing epitopes. Proc. Natl Acad. Sci. USA 116, 13474–13479 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31213541</ArticleId><ArticleId IdType="pmc">6612916</ArticleId><ArticleId IdType="doi">10.1073/pnas.1816300116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer-Babajew, D. et al. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature 613, 735–742 (2023).</Citation></Reference><Reference><Citation>Goodwin, E., Gibbs, J. S., Yewdell, J. W., Eisenlohr, L. C. &amp; Hensley, S. E. Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice. Preprint at bioRxiv https://doi.org/10.1101/2024.04.12.589218 (2024).</Citation></Reference><Reference><Citation>Lanzavecchia, A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8, 773–793 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2188679</ArticleId><ArticleId IdType="doi">10.1146/annurev.iy.08.040190.004013</ArticleId></ArticleIdList></Reference><Reference><Citation>Biavasco, R. &amp; De Giovanni, M. The relative positioning of B and T cell epitopes drives immunodominance. Vaccines 10, 1227 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36016115</ArticleId><ArticleId IdType="pmc">9413633</ArticleId><ArticleId IdType="doi">10.3390/vaccines10081227</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, F., Smith, P. &amp; Ravetch, J. V. Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms. J. Immunol. 192, 3021–3028 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24563255</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1302934</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, D. J., Forrest, S., Ackley, D. H. &amp; Perelson, A. S. Variable efficacy of repeated annual influenza vaccination. Proc. Natl Acad. Sci. USA 96, 14001–14006 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10570188</ArticleId><ArticleId IdType="pmc">24180</ArticleId><ArticleId IdType="doi">10.1073/pnas.96.24.14001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarnitsyna, V. I., Lavine, J., Ellebedy, A., Ahmed, R. &amp; Antia, R. Multi-epitope models explain how pre-existing antibodies affect the generation of broadly protective responses to influenza. PLoS Pathog. 12, e1005692 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27336297</ArticleId><ArticleId IdType="pmc">4918916</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1005692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi, A. et al. Omicron-specific naive B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine. Preprint at bioRxiv https://doi.org/10.1101/2024.05.13.594034 (2024).</Citation></Reference><Reference><Citation>Schiepers, A., Van’t Wout, M. F. L., Hobbs, A., Mesin, L. &amp; Victora, G. D. Opposing effects of pre-existing antibody and memory T cell help on the dynamics of recall germinal centers. Immunity 57, 1618–1628 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38838672</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.05.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng, H. F. et al. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat. Commun. 14, 5851 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37730701</ArticleId><ArticleId IdType="pmc">10511551</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41537-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, D.-Y. et al. Durability of XBB.1.5 vaccines against Omicron subvariants. N. Engl. J. Med. 390, 2124–2127 (2024).</Citation></Reference><Reference><Citation>Amitai, A. et al. Defining and manipulating B cell immunodominance hierarchies to elicit broadly neutralizing antibody responses against influenza virus. Cell Syst. 11, 573–588 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33031741</ArticleId><ArticleId IdType="pmc">7746579</ArticleId><ArticleId IdType="doi">10.1016/j.cels.2020.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. Optimal sequential immunization can focus antibody responses against diversity loss and distraction. PLoS Comput. Biol. 13, e1005336 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28135270</ArticleId><ArticleId IdType="pmc">5279722</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1005336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprenger, K. G., Louveau, J. E., Murugan, P. M. &amp; Chakraborty, A. K. Optimizing immunization protocols to elicit broadly neutralizing antibodies. Proc. Natl Acad. Sci. USA 117, 20077–20087 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32747563</ArticleId><ArticleId IdType="pmc">7443869</ArticleId><ArticleId IdType="doi">10.1073/pnas.1919329117</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan, R. et al. Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity. Front. Immunol. 13, 985478 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36263031</ArticleId><ArticleId IdType="pmc">9574365</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.985478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>